Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Glioma 7Wilms Tumor 6Rhabdoid Tumor 5Osteosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Multiple Myeloma 5Medulloblastoma 5Lymphoma, Non-Hodgkin 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Sarcoma 4Rhabdomyosarcoma 4Lymphoma 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Central Nervous System Neoplasms 4Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Burkitt Lymphoma 3Sarcoma, Ewing 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Mycosis Fungoides 2Melanoma 2Malignant Solid Neoplasm 2Lymphoma, T-Cell 2

Interventions

erdafitinib 1X-Rays 1Specimen Handling 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Magnetic Resonance Spectroscopy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial ependymoma × X-Rays × 30 days × Clear all
NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡